Salvianolic acid A salt complex and preparation method and application thereof

A technology of salvianolic acid and compound, applied in the fields of medicine and pharmacy, can solve the problems of difficulty in ensuring long-term stability, easy to be oxidized, poor stability of salvianolic acid A, etc. Myocardial ischemia-reperfusion injury

Inactive Publication Date: 2019-11-05
CHIATAI QINGCHUNBAO PHARMA
View PDF8 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, salvianolic acid A has poor stability, is easily oxidized, and it is difficult to ensure its long-term stability after it is made into various dosage forms.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Salvianolic acid A salt complex and preparation method and application thereof
  • Salvianolic acid A salt complex and preparation method and application thereof
  • Salvianolic acid A salt complex and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] The preparation method of the salvianolic acid A salt compound of the present invention can refer to the method disclosed in CN 106748733A, and the preparation of the salvianolic acid A sodium compound is taken as an example below to illustrate:

[0048] Dissolve 1250 g of salvianolic acid A in 1010 mL of water, add 5% sodium hydroxide solution to adjust the pH to 3.6, filter, collect the precipitate, and dry under reduced pressure to obtain 767 g of salvianolic acid A sodium complex with a purity of 99.90%.

[0049] Other salvianolic acid A salt complexes can be prepared in the same way.

Embodiment 2

[0051] Accurately weigh an appropriate amount of the sodium salvianolic acid A compound prepared in Example 1, dissolve it in 5% glucose injection, and dilute it step by step to obtain different concentrations of medicinal solutions; take dog venous blood, and centrifuge at 800r / min after anticoagulation Separation of PRP for 10 minutes, separation of PPP by centrifugation at 2000r / min for 10 minutes, and 300 μL of each portion were distributed in colorimetric tubes. After confirming that PRP and PPP are suitable and available, 10 μL of liquid medicine were added, and after mixing, the final concentrations of the liquid medicines were respectively 1.41, 0.85, 0.51, 0.31, 0.18, 0.11, 0.07 and 0.04mg / mL, add 10μL 5% glucose injection in the control group; preheat the instrument for 5min, and detect platelets within 5min after adding 10μL ADP by Born nephelometric method The maximum aggregation rate (A max ), and calculate the aggregation inhibition rate according to formula 1. ...

Embodiment 3

[0058] Accurately weigh the appropriate amount of the sodium salvianolic acid A compound prepared in Example 1, dissolve it in distilled water and then dilute it with Krebs-Henseleit test solution to obtain medicinal solutions with different concentration gradients; healthy Wistar rats were taken, and quickly removed after anesthetized and killed. The upper part of the thoracic aorta strip was uniformly cut into 3-4mm vascular rings, suspended in the isolated perfusion device, inserted into two stainless steel hooks parallel to each other up and down, and the tension changes were recorded by the Pclab-UE biological signal acquisition system through the tension sensor. After equilibrating with K-H solution for 2 hours, add 40mmol / L KCl to shrink the vascular ring twice until the contraction is stable; pre-shrink the vascular ring with 40mmol / L KCl or 0.8μmol / L phenylephrine hydrochloride for 9min, add 0.002% For ascorbic acid, add different concentrations of salvianolic acid A s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a salvianolic acid A salt complex. The salvianolic acid A salt complex is prepared from diad salvianolic acid A and a positive ion, the salvianolic acid A salt complex has the chemical construction (being defined as in the specification); and the salvianolic acid A salt complex has the pharmacological activity of anti-myocardial ischemia treating, anti-myocardial ischemia reperfusion injury treating, and platelet aggregation inhibition, and can be applied to preparation of medicines with the related curative effect. The preparation method of the salvianolic acid A salt complex is simple, easy to produce, and more stable relative to the salvianolic acid A.

Description

[0001] (1) Technical field [0002] The invention belongs to the technical field of medicine and pharmacy, and in particular relates to a salvianolic acid A salt complex and a preparation method thereof, and its application in the preparation of drugs for treating myocardial ischemia, myocardial ischemia-reperfusion injury, and platelet aggregation . [0003] (2) Background technology [0004] Salvianolic acid A (Salvianic acid A) is a water-soluble phenolic acid compound that was first extracted and isolated from the dry roots and rhizomes of Salvia miltiorrhiza, a labiatae plant, by Professor Li Lianniang in 1984. It has a variety of pharmacological activities. , such as anti-inflammatory, anti-oxidative and neuroprotective effects (Li YJ, Duan CL, Liu JX.Salvianolic acid A promotes the acceleration of neovascularization in the ischemic rat myocardium and the functions of endothelial progenitor cells[J].J Ethnopharmacol,2014,151 :218-227.). With further research, scholars h...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/216A61K36/537A61P9/10A61P7/02
CPCA61K31/216A61K36/537A61P9/10A61P7/02
Inventor 潘迎锋刘雳黄安皓付玲珠张丽张平
Owner CHIATAI QINGCHUNBAO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products